Needham & Company initiates coverage on Chelsea Therapeutics (Nasdaq: CHTP) with a Buy rating. PT $7.

Needham analyst says, "CH-4051 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE